RxDoctor Payments Data

Susan Hall, MD

Family Medicine · Tehachapi, CANPI 1578649067

Payments from drug & device makers

$388in general payments, 2019–2025

Across 15 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$86
  • Amarin Pharma, Inc.$83
  • Boehringer Ingelheim$78
  • GSK$37
  • Pfizer$23
  • Medtronic$21
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$388 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$207,351
Medicare patients
276
Services billed
4,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$112,537
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$57,279
EliquisApixaban68$54,438
JanuviaSitagliptin Phosphate42$40,618
TrulicityDulaglutide28$39,065
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$25,223
LinzessLinaclotide27$19,691
Breo ElliptaFluticasone/Vilanterol37$16,138
FarxigaDapagliflozin Propanediol14$13,589
Tresiba Flextouch U-100Insulin Degludec34$13,513
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$13,511
Advair HfaFluticasone Propion/Salmeterol24$10,837
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,963
Incruse ElliptaUmeclidinium Bromide12$7,091
Arnuity ElliptaFluticasone Furoate12$6,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$78$112,53790 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$37$100,837155 claims
PfizerEliquis$23$54,43868 claims
MerckJanuvia$15$40,61842 claims
Lilly USA, LLCTrulicity$13$39,06528 claims
AstraZenecaBreztri Aerosphere, Farxiga$18$38,81242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,533 family medicine providers in California.

Other family medicine in Tehachapi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →